Method of treating the syndrome of lipodystrophy

Details Method of treating the syndrome of lipodystrophy Method of treating the syndrome of lipodystrophy

2005-01-25

2005-01-25

Henley, III, Raymond (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

06846831

ABSTRACT:
Methods of treating a human suffering from the Syndrome of Lipodystrophy or one or more HIV-related abnormalities included therein are provided. One method may include administering, by a pharmaceutically effective mode, a drug composition comprising an opioidergic agent, or alternatively, an opioidergic agent and an insulin secretagogue. The method may also include administering, by a pharmaceutically effective mode, a drug composition comprising an opiate agonist and opiate antagonist, or alternatively, an opiate agonist, opiate antagonist and an insulin secretagogue.

REFERENCES:
patent: 4055175 (1977-10-01), Clemens et al.
patent: 4217353 (1980-08-01), Smith, Jr.
patent: 4272540 (1981-06-01), Razdan et al.
patent: 4451470 (1984-05-01), Ganti
patent: 4478840 (1984-10-01), Smith, Jr.
patent: 4511570 (1985-04-01), Tuttle
patent: 4619936 (1986-10-01), Balkanyi et al.
patent: 4760069 (1988-07-01), Rzeszotarski et al.
patent: 4857533 (1989-08-01), Sherman et al.
patent: 4863928 (1989-09-01), Atkinson et al.
patent: 4877791 (1989-10-01), Sherman
patent: 4880813 (1989-11-01), Frost
patent: 4882335 (1989-11-01), Sinclair
patent: 4888346 (1989-12-01), Bihari et al.
patent: 4994466 (1991-02-01), Sherman
patent: 5013739 (1991-05-01), Bihari et al.
patent: 5086058 (1992-02-01), Sinclair et al.
patent: 5356900 (1994-10-01), Bihari et al.
patent: 5468755 (1995-11-01), Cincotta et al.
patent: 5578645 (1996-11-01), Askanazi et al.
patent: 5626860 (1997-05-01), Cincotta et al.
patent: 5727570 (1998-03-01), Clemens
patent: 5830895 (1998-11-01), Cincotta et al.
patent: 5863555 (1999-01-01), Heiber et al.
patent: 5878750 (1999-03-01), Clemens
patent: 6026817 (2000-02-01), Clemens
patent: 6159500 (2000-12-01), Demopoulos et al.
patent: 6190691 (2001-02-01), Mak
patent: 6262062 (2001-07-01), Clemens
patent: 6528520 (2003-03-01), Clemens
patent: 20030036546 (2003-02-01), Clemens
patent: 20030105121 (2003-06-01), Bihari
patent: 0 078 434 (1983-05-01), None
patent: 0 541 192 (1993-05-01), None
patent: 2 045 758 (1980-11-01), None
patent: WO 9718781 (1997-05-01), None
patent: WO 9735608 (1997-10-01), None
patent: WO 9904795 (1999-02-01), None
patent: WO 9959997 (1999-11-01), None
patent: WO 02100390 (2002-12-01), None
patent: WO 03026635 (2003-04-01), None
Liu, et al., “Activation Of Opioid μ Receptor By Loperamide To Lower Plasma Glucose In Streptozotocin-induced Diabetic Rats”, Neuroscience Letters, vol. 265, No. 3, pp. 183-186, (Apr. 23, 1999).
Riepl, et al., “Pancreatic Polypeptide Release Induced By Ceruletide, Sham Feeding, And Hypoglycemia Is Suppressed By Loperamide”, European Journal of Clinical Investigation, vol. 23, No. Suppl. 1, p. A10, (1993).
Marsboom, et al., “Loperamide (R 18 553), A Novel Type Of Antidiarrheal Agent”, Janssen Pharmaceutica, Research Laboratoria, vol. 24, No. 10, pp. 1645-1649, (Oct. 1974).
Carr, et al., “The Role Of Opioids In Feeding And Reward Elicited By Lateral Hypothalamic Electrical Stimulation”, Life Sciences, Pergamon Press, vol. 33, No. Suppl. 1, pp. 563-566, (1983).
Gautret, et al., “Vagally Mediated Reflex And Cardiac Slowing Induced By Loperamide In Rats”, European Journal of Pharmacology, vol. 107, No. 2, pp. 157-160, (1985).
Riepl, el al., “Suppression Of Vagus-Mediated Pancreatic Polypeptide Release By The μ-Opiate Receptor Agonist Loperamide in Man”, British Journal of Clinical Pharmacology, vol. 42, No. 3, pp. 371-377, (1996).
Green, et al., “Effect of Enkephalins And Morphine On Insulin Secretion From Isolated Rat Islets”, Diabetologia, vol. 19, No. 2, pp. 158-161, (Aug. 1980).
Ahlgren, Gunnar, “Insulin—Like Action Of Morphine And Certain Morphine Derivatives”, Skank, Arch Physiol, 58, pp. 153-172, (1930).
Green, et al., “Opioid Peptide Effects on Isolated Hepatocytes And Islets Of Langerhans”, International Congress Series, 700 (Diabetes 1985), pp. 258-262, (1986).
Bailey, et al., “Increased Responsiveness To Glcoregulatory Effect of Opiates On Obese-Diabetic ob/ob/Mice”, Diabetologia, vol. 30, No. 1, pp. 33-37, (Jan. 1987).
The Merck Index 10th Ed., 1983 p. 491-492.
The Merck Index 14th Ed., 1996 p. 1052 [Metyrosine].
R. Landgraf et al.; “Prolactin: A Diabetogenic Hormone”, Diabetologia 13, 1977, pp. 99-104, 1976.
The Pharmacological Basis of Therapeutics, Seventh Edition (Chapter 18, p. 383), 1985.
Atkinson et al., “Effects of Long-Term Therapy with Nultrexone on Body Weight in Obesity” Clin. Pharmacol. Ther. 10/85: pp. 419-422, publication date not available.
J.R. Givens et al.; “Reduction of Hyperinsulinemia” J. Clin. Endocr. & Metab. 64/2, 1987, pp. 377-382.
G. R. Van Loon et al.; Endocrinology; vol. 109, p. 46, 1981.
R. Vink et al.; “K-Opioid Antagonist Improves Cellular Bioenergetics and Recovery After Traumatic Brain Injury” Am. J. Physiol. 261, 1991.
Sohel et al. “Influence of Adrenergic Blockers and Antilipemic Agents on Pharmacodynamic Actions of Morphine in Carbon Tetrachloride-Treated Rats.” Toxicol Appl Pharmacol 27(3):477-483, Mar., 1974.
Stern et al. “Lack of Awareness and Treatment of Hyperlipidemia in Type II Diabetes in a Community Survey.” JAMA 262(3):360-4, Jul., 1989.
Herz A. “Bidirectional Effects of Opioids in Motivational Processes and the Involvement of D1 Dopamine Receptors.” NIDA Res Monogr 1988;90:17-26.
Herz A.; “Opioid Reward Mechanisms: A Key Role in Drug Abuse?” Can J Physiol Pharmacol 76, 3:252-8, 1998.
Pan Z.Z.; “mu-Opposing Actions of the Kappa-Opioid Receptor” Thrends Pharmacol Sci; 19, 3: 94-8, 1998.
Porotoghese, et al.; “Binaltorphimine and Nor-Binal Torphimine, Potent and Selective κ-Opioid Receptor Antagonists” Life Sciences 40: 1287-92, 1987.
Jones et al.; Journal of Medicinal Chemistry 41, 25: 4911-4, 1998.
Merz et al.; Advances in biochemical psychopharmacology, vol. 8:91-107, 1974.
Porotoghese et al.; “TENA, A Selective Kappa Opioid Receptor Antagonist” Life Sciences 36:801-5, 1984.
Lewis J.W.; “Buprenorphine” Drug and Alcohol Dependence; 14:363-372, 1985.
McQuay J.J. et al.; “Clinical Effects of Buprenorphine During and After Operation” Br J. Anaesth; 52:1013-19, 1980.
Ruppin H.; “Loperamide—A Potent Antidiarrhoeal Drug with Actions Along the Alimentary Tract” Aliment Pharmacol Ther 1987, 1(3): 179-190.
Caldara R. et al.; “Effect of Loperamide, a Peripheral Opiate Agonist, on Circulating Glucose, Free Fatty Acids, Insulin, C-Peptide and Pituitary Hormones in Healthy Man” Eur J. Clin Pharmacol; 21, 3:185-8, 1981.
Buzi F. et al.; “Loperamide Test: a Simple and Highly Specific Screening Test for Hypercortisolism in Children and Adolescents” Acta Paediatr; 86, 11: 1177-80, 1997.
Foss et al.; “Restoration of Glucose Homeostasis in Insulin-Dependent Diabetic Subjects”; Diabetes, 31:46-52, 1982.
Pfeifer et al.; “Insulin Secretion in Diabetes Mellitus”; The American Journal of Medicine, 70:579-588, 1981.
Felber et al.; Effect of a 3-Day Fast on Glucose Storage and Oxidation in Obese Hyperinsulinemic Diabetics; Metabolism, 30,2; 184-189 and Diabetologia, 20:39-44, 1981.
Edelman, S.V.; “Prescribing Oral Antidiabetic Agents: General Considerations”; Clinical Diabetes 16,1:37-40, 1998.
Cole, Evaluation of Chronic Opioid Receptor Antagonist Effects Upon Weight and Intake Measures in Lean and Obese Zucker Rats, Peptides, vol. 18, No. 8, 1997 pp. 1201-1207.
Shaw, The Effect of the Opiod Antagonist LY255582 on Body Weight of the Obese Zucker Rat, International Journal of Obesity, vol. 15, No. 6, Jun. 1991, pp. 387-395.
Givens, et al., Reduction of Hyperinsulinemia and Insulin Resistance by Opiate Receptor Blockade in the Polycystic Ovary Syndrome with Acanthosis Nigricans, Journal of Clinical Endocrinology and Metabolism, New York, NY, vol. 64, No. 2, Feb. 1987, pp. 377-382.
Wexler,

Affiliated with

Also associated with

Rating

Method of treating the syndrome of lipodystrophy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating the syndrome of lipodystrophy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating the syndrome of lipodystrophy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3369472